Crescent Biopharma's total assets for Q2 2025 were $157.43M, an increase of 2527.31% from the previous quarter. CBIO total liabilities were $18.18M for the fiscal quarter, a 594.67% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.